<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13300">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01929707</url>
  </required_header>
  <id_info>
    <org_study_id>14935</org_study_id>
    <secondary_id>I6R-MC-DLAA</secondary_id>
    <nct_id>NCT01929707</nct_id>
  </id_info>
  <brief_title>A Study of LY3050258 in Healthy Volunteers</brief_title>
  <official_title>A Single-Dose, Dose Escalation, Safety, Tolerability, and Pharmacokinetic Study of LY3050258</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety and how well the body will handle a
      single dose of increasing strength of study drug LY3050258.  Each participant will receive
      LY3050258 or placebo once, in each of two dosing periods.  At least seven days will pass
      between doses. This study will last approximately 45 days for each participant.  Screening
      is required within 28 days before the start of the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline to Study Completion (estimated as 45 days)</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK):  Maximum Concentration (Cmax) of LY3050258</measure>
    <time_frame>Predose up to 21 days postdose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) of LY3050258</measure>
    <time_frame>Predose up to 21 days postdose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>LY3050258</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single escalating dose of LY3050258 (2 milligram [mg] up to 200 mg) administered in up to two of two periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of placebo matching LY3050258 administered in up to one of two periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3050258</intervention_name>
    <arm_group_label>LY3050258</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males or healthy postmenopausal females, including Japanese participants

          -  Have a body mass index of 18 to 35 kilograms per square meter (kg/m^2)

        Exclusion Criteria:

          -  An abnormal sitting blood pressure as determined by the investigator

          -  Any abnormality in the 12-lead electrocardiogram that, in the opinion of the
             investigator, places the participant at an unacceptable risk for study participation

          -  Current use of statins within the last 3 months prior to dosing

          -  Current use or previous use of anabolic steroids in the preceding 6 months prior to
             dosing

          -  Use of dehydroepiandrosterone, other potential over-the-counter (OTC) steroidal
             supplements, or other nutritional products intended to have weight-reduction and/or
             performance-enhancing effects within 21 days prior to dosing
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 16, 2013</lastchanged_date>
  <firstreceived_date>August 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
